Kymera Therapeutics, Inc. - Common Stock (KYMR) stock analysis

KYMR · Kymera Therapeutics, Inc. - Common Stock

Latest recorded price: USD 125.85

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth -5.7%, free cash flow margin -597.6%, ROIC -45.4%. The model flags 2 risk signals for this company (2 high severity).

Similar companies in Healthcare